Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INSTEAD
NCT05385432Phase 3Recruiting
- Sponsor
- University Hospital Tours
- Start
- Nov 2023
- Primary completion
- Dec 2030
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in renal transplant rejection (RTR) comparing rabbit antithymocyte globulin (rATG) with Basiliximab (2 arms). Primary endpoint: Biopsy-proven acute rejection at 1 year. Started Nov 2023; status: recruiting.
02
Drugs
antithymocyte globulin rabbitbasiliximab
03
Conditions
renal transplant rejection (RTR)
Beyond the preview
Go deeper on NCT05385432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05385432.